Europe’s vaccination process was expected to be well-orchestrated and efficient. So far, it’s been neither. Sabrina Tavernise, a national correspondent for The Times, spoke with our colleague Matina Stevis-Gridneff about Europe’s problems and why things could get worse before they get better.
Guest: Matina Stevis-Gridneff, the Brussels correspondent for The New York Times, covering the European Union.
- A cascade of small decisions has led to increasingly long delays in the European Union’s inoculation efforts. While Washington went into business with the drug companies, Brussels took a conservative, budget-conscious approach that left the open market largely untouched. And it has paid for it.
- Falling behind the pace of vaccine rollouts in countries like Britain, the United States and Israel, Europe is now tightening export rules in a bid to speed up its inoculation campaign and stem political criticism.
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.